AbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

Dr. Mehmet Oz holds millions of dollars worth of shares in health insurance, fertility, pharmaceutical and vitamin companies.

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...

We recently compiled a list of the Top 10 Stocks to Buy According to Lee Munder Capital Group. In this article, we are going ...

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie ...

That's a good analogy for AbbVie, which must continually create new products to replace treatments whose patents expire. The great news is that AbbVie has seemingly done that with its new ...

and the oncology ADC pipeline positioned to produce additional products beyond Elahere. Overall, I continue to see AbbVie as one of the better run big pharma companies that is well-positioned to ...

Pharmaceutical powerhouse AbbVie(NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while raising ...